Edge Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Edge Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,000	Closed	-$25K	–	972
2017 Q4	$25K	Buy	+1,000	New	+$20.1K	﹤0.01%	644

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Edge Advisors's CNCE Position: Q1 2018 in Review

Edge Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2018, closing a stake of 1,000 shares — an estimated $25K sold.

Edge Advisors first reported a position in CNCE in Q4 2017 and held it in 1 quarter. The position peaked at $25K in Q4 2017. 123 funds tracked by Wall St. Rank hold CNCE as of Q1 2018.

Edge Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Edge Advisors sold 1,000 Concert Pharmaceuticals, Inc. shares in Q1 2018, an estimated $25K.
Edge Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
Edge Advisors's Concert Pharmaceuticals, Inc. position peaked at $25K in Q4 2017.
123 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2018.

Based on Edge Advisors's 13F filing for Q1 2018, filed 15 May 2018.